about
Degranulating mast cells in fibrotic regions of human tumors and evidence that mast cell heparin interferes with the growth of tumor cells through a mechanism involving fibroblastsOvarian cancer, the coagulation pathway, and inflammationM402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasisImpact of venous thromboembolism and anticoagulation on cancer and cancer survivalConformational changes of 1-4-glucopyranosyl residues of a sulfated C-C linked hexasaccharideSignificance of neo-angiogenesis and immuno-surveillance cells in squamous cell carcinoma of the tongue.Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer.Deep vein thrombosis (DVT) in advanced cancer patients with lower extremity edema referred for assessment.Protease-activated receptors in cancer: A systematic review.Low-molecular-weight heparins and angiogenesis.Venous thromboembolic events and organ-specific occult cancers: a review and meta-analysis.Heparin and related drugs: beyond anticoagulant activity.Heparins attenuate cancer metastasis: are selectins the link?Heparan sulfate-protein binding specificity.Exploring bacterial heparinase II activities with defined substrates.Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis.Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparinA 3.0-kDa low molecular weight heparin promotes gastric ulcer healing in rats.Heparin Mimetics: Their Therapeutic Potential.Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results.The influence of low molecular weight heparin on the intravascular activation of the coagulation system in patients with acute leukemia during induction chemotherapy--report of a prospective randomized study.Biomacromolecules as carriers in drug delivery and tissue engineering.
P2860
Q24814173-725BD014-6528-4B12-8CBF-DCC371256221Q24816796-1C655C67-EF62-4E06-95BB-A97A3719DD5DQ28743550-EEBD2CD2-0F45-4B93-844A-FF29E9D7961EQ33561203-474453FF-64C3-4269-B713-144D2ABB2AB9Q33654719-AD6C598D-7EE3-4A2E-AB7A-2FAB225B5C6DQ34803861-56C9DDEF-F1A9-498A-90C1-C134AF2CAD60Q35863905-1762AF3C-9B57-449D-A9FB-636C532D5709Q36106603-12CBE62A-6E4B-46D6-8CD9-73FB8232DEEBQ36121203-9E310755-F7AC-407D-9927-13C1BC2AC4A2Q36414904-AB3641D8-6FAD-45F2-BC6C-403FAAA546F8Q37088527-8403BA33-C261-4D6E-ABC6-81D5684958A6Q37105310-14D224BE-B1F8-4929-A06E-3958F93A26F7Q37500092-58770CD8-14D3-4577-9A7D-44522687D752Q38134808-D332C6BB-B10F-4457-9EBD-16563E83EDADQ38299516-DC9E6588-7540-47F6-BC27-D12328C95EB7Q39307644-4F79F250-D25C-4ADC-AA07-621D12DF662BQ40661233-018BA0FA-3D73-4433-9C26-1A82AD0B09FCQ40764905-850F2EAB-834E-42DE-9DCA-47CDC6655BFFQ47159791-18CF7D72-75E3-4788-AFEF-12B1530A1EE8Q47175930-3A240D4F-0AB0-4F5E-8561-CFD6CC5373EEQ47180709-D1AD7EF1-1018-48D9-A703-AA3A68AC2FFDQ55114332-0F1279F1-F6F9-41CA-8877-2AB5152543F6
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Low-molecular-weight heparin and cancer.
@ast
Low-molecular-weight heparin and cancer.
@en
Low-molecular-weight heparin and cancer.
@nl
type
label
Low-molecular-weight heparin and cancer.
@ast
Low-molecular-weight heparin and cancer.
@en
Low-molecular-weight heparin and cancer.
@nl
prefLabel
Low-molecular-weight heparin and cancer.
@ast
Low-molecular-weight heparin and cancer.
@en
Low-molecular-weight heparin and cancer.
@nl
P2093
P356
P1476
Low-molecular-weight heparin and cancer.
@en
P2093
Mamourian AC
Ornstein DL
Zacharski LR
P356
10.1055/S-2000-9499
P478
26 Suppl 1
P577
2000-01-01T00:00:00Z